Design Therapeutics (DSGN) Projected to Release Quarterly Earnings on Wednesday

Design Therapeutics (NASDAQ:DSGN) is anticipated to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 9:30 AM ET.

Design Therapeutics (NASDAQ:DSGN) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.02. On average, analysts expect Design Therapeutics to post ($1.41) EPS for the current fiscal year and ($1.63) EPS for the next fiscal year.

Design Therapeutics Price Performance

Design Therapeutics stock opened at $10.68 on Monday. The stock has a market capitalization of $668.35 million, a PE ratio of -9.05 and a beta of 1.73. Design Therapeutics has a 12 month low of $6.16 and a 12 month high of $17.25. The business has a 50 day simple moving average of $12.66 and a 200-day simple moving average of $12.13.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Wells Fargo & Company initiated coverage on Design Therapeutics in a research note on Friday, October 2nd. They issued an “overweight” rating and a $26.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Design Therapeutics in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Design Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $17.86.

About Design Therapeutics

Design Therapeutics, Inc (NASDAQ: DSGN) is a clinical-stage biotechnology company developing small-molecule medicines for genetic diseases caused by nucleotide repeat expansions. The company’s GeneTAC, or gene-targeted activation compound, platform is designed to reactivate genes that have been silenced by these repeat expansions, with the goal of restoring production of beneficial proteins.

The company’s research has focused on disorders affecting the nervous system, muscles and eyes.